Vignesh et al. in 2008 reported that IPM is the drug of choice against MDR bacteria and also that only 28% of GNB from HIV patients were resistant to IPM.[4] We found that 45% of GNB were resistant to IPM which indicates that IPM resistance rate has been increasing among HIV population. Another study demonstrated clonal similarity between blaNDM-1 strains and difference in antibiotic resistance profiles based on 1–5 amino acid substitutions.[1] In our study, blaNDM isolates were found clonally different by random amplified polymorphic DNA analysis. In a study from Ecuador, blaNDM-positive K. pneumoniae from HIV patients exhibited co-positivity to blaCTX-M and blaSHV genes.[5] Our study reports first time the positivity of blaNDM-1 and its variant blaNDM-5 among GNB from HIV patients in South India. Continuous monitoring of blaNDM genes among GNB is needed due to XDR and MDR profiles which could help in the timely treatment of bacterial infections in HIV patients.